Noggin CRISPR/Cas9 KO Plasmid (h2): sc-402090-KO-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Noggin CRISPR/Cas9 Knockout (KO) Plasmid (h2) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Noggin genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Noggin Antibody (2C10): sc-293439
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Noggin CRISPR/Cas9 KO Plasmid (h2) | sc-402090-KO-2 | 20 µg | $397.00 |
Overview
NOG encodes noggin, a secreted glycoprotein that binds and neutralizes BMP ligands (notably BMP2, BMP4, and BMP7), thereby tuning BMP/TGF-β superfamily signaling gradients during development and adult tissue homeostasis. By antagonizing BMP receptor activation and downstream SMAD1/5/8 phosphorylation, noggin influences cell fate decisions, osteogenic and chondrogenic differentiation, and patterning processes in mesenchymal and neural lineages. Altered NOG activity is linked to dysregulated skeletal morphogenesis and joint formation, and it is frequently studied in contexts involving aberrant BMP-driven remodeling and differentiation. As a key extracellular modulator of morphogen signaling, noggin is relevant to investigations of developmental biology, bone and cartilage biology, and pathway cross-talk with WNT and FGF programs.
Noggin CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the NOG gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NOG together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NOG open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Noggin protein expression.
This CRISPR knockout system enables efficient generation of NOG-deficient cell models for investigation of Noggin signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting NOG exon(s) critical for Noggin function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple NOG genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Noggin CRISPR/Cas9 KO Plasmid (h) and Noggin CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NOG locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Noggin HDR Plasmid (h) and Noggin HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NOG homology arms to support homology-directed repair at defined NOG target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.